BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15928040)

  • 21. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling.
    Honorat JF; Ragab A; Lamant L; Delsol G; Ragab-Thomas J
    Blood; 2006 May; 107(10):4130-8. PubMed ID: 16469875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.
    Hübinger G; Scheffrahn I; Müller E; Bai R; Duyster J; Morris SW; Schrezenmeier H; Bergmann L
    Exp Hematol; 1999 Dec; 27(12):1796-805. PubMed ID: 10641597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.
    Zamo A; Chiarle R; Piva R; Howes J; Fan Y; Chilosi M; Levy DE; Inghirami G
    Oncogene; 2002 Feb; 21(7):1038-47. PubMed ID: 11850821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
    Galietta A; Gunby RH; Redaelli S; Stano P; Carniti C; Bachi A; Tucker PW; Tartari CJ; Huang CJ; Colombo E; Pulford K; Puttini M; Piazza RG; Ruchatz H; Villa A; Donella-Deana A; Marin O; Perrotti D; Gambacorti-Passerini C
    Blood; 2007 Oct; 110(7):2600-9. PubMed ID: 17537995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.
    Quintanilla-Martinez L; Pittaluga S; Miething C; Klier M; Rudelius M; Davies-Hill T; Anastasov N; Martinez A; Vivero A; Duyster J; Jaffe ES; Fend F; Raffeld M
    Blood; 2006 Sep; 108(6):2029-36. PubMed ID: 16709933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
    Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
    Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
    Wan W; Albom MS; Lu L; Quail MR; Becknell NC; Weinberg LR; Reddy DR; Holskin BP; Angeles TS; Underiner TL; Meyer SL; Hudkins RL; Dorsey BD; Ator MA; Ruggeri BA; Cheng M
    Blood; 2006 Feb; 107(4):1617-23. PubMed ID: 16254137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
    Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
    Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells.
    Shi X; Franko B; Frantz C; Amin HM; Lai R
    Br J Haematol; 2006 Oct; 135(1):26-32. PubMed ID: 16939498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation.
    Fernandez-Vidal A; Mazars A; Gautier EF; Prévost G; Payrastre B; Manenti S
    Cell Cycle; 2009 May; 8(9):1373-9. PubMed ID: 19305144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility.
    Cutrupi S; Baldanzi G; Gramaglia D; Maffè A; Schaap D; Giraudo E; van Blitterswijk W; Bussolino F; Comoglio PM; Graziani A
    EMBO J; 2000 Sep; 19(17):4614-22. PubMed ID: 10970854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
    Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
    Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
    Armanious H; Gelebart P; Anand M; Lai R
    Cell Signal; 2013 Feb; 25(2):381-8. PubMed ID: 23153582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.
    Fawal M; Armstrong F; Ollier S; Dupont H; Touriol C; Monsarrat B; Delsol G; Payrastre B; Morello D
    Blood; 2006 Oct; 108(8):2780-8. PubMed ID: 16835382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.
    Piva R; Pellegrino E; Mattioli M; Agnelli L; Lombardi L; Boccalatte F; Costa G; Ruggeri BA; Cheng M; Chiarle R; Palestro G; Neri A; Inghirami G
    J Clin Invest; 2006 Dec; 116(12):3171-82. PubMed ID: 17111047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
    Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
    J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.